Crinetics Pharmaceuticals (CRNX) Q3 2025 earnings summary

Executive summary

• PALSONIFY (paltusotine) launched in the U.S. after FDA approval for acromegaly, showing strong early commercial momentum, broad prescriber engagement, and positive reimbursement trends.

• Pipeline momentum continues with late-stage programs for carcinoid syndrome, congenital adrenal hyperplasia (CAH), ACTH-dependent Cushing's syndrome, and neuroendocrine tumors, with multiple clinical and regulatory milestones expected.

• Multiple commercial and clinical catalysts are anticipated over the next 24+ months, including key data readouts and regulatory decisions.

• Cash runway is projected into 2029, supporting commercialization and pipeline advancement.

• European review of PALSONIFY ongoing, with potential EMA decision in H1 2026.

Financial highlights

• Q3 2025 revenue was $0.1 million, all from licensing agreements; no product revenue recognized in Q3 due to timing of approval.

• R&D expenses were $90.5 million in Q3 2025, up from $80.3 million in Q2 and $61.9 million in Q3 2024, reflecting increased clinical activity and personnel costs.

• SG&A expenses were $52.3 million in Q3 2025, up from $49.8 million in Q2 and $25.9 million in Q3 2024, driven by launch investments and headcount growth.

• Net loss for Q3 2025 was $130.1 million, up 69% year-over-year; net loss per share was $1.38.

• Cash, cash equivalents, and investments totaled $1.1 billion as of September 30, 2025.

Outlook and guidance

• Cash runway expected to last into 2029, supporting commercialization and pipeline development.

• 2025 net cash used in operations/cash burn guidance is $340–$370 million.

• Launch metrics, including revenue, new patient starts, and prescriber numbers, will be provided after a full quarter in Q1 2026.

• Expects to initiate pediatric and additional adult trials for atumelnant and new studies for CRN09682 in late 2025 and 2026.